STOCK TITAN

Leap Therapeutics, Inc. - $LPTX STOCK NEWS

Welcome to our dedicated page for Leap Therapeutics news (Ticker: $LPTX), a resource for investors and traders seeking the latest updates and insights on Leap Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Leap Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Leap Therapeutics's position in the market.

Rhea-AI Summary
Leap Therapeutics, Inc. (Nasdaq:LPTX) reported financial results for the second quarter ended June 30, 2023. The company announced positive data from Phase 2 studies of DKN-01 in treating colorectal and gastric cancer, leading to the initiation of randomized controlled trials. The company also presented long-term follow-up data at the 2023 ASCO Annual Meeting, demonstrating promising results. Financially, the company's net loss decreased to $13.4 million in the second quarter of 2023, compared to $17.0 million for the same period in 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
-
Rhea-AI Summary
Leap Therapeutics initiates Phase 2 study for its anti-DKK1 antibody in colorectal cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.19%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.24%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.67%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.64%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.89%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.75%
Tags
Leap Therapeutics, Inc.

Nasdaq:LPTX

LPTX Rankings

LPTX Stock Data

105.23M
24.77M
2.96%
30.37%
4.44%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
CAMBRIDGE

About LPTX

leap therapeutics (nasdaq: lptx) is a clinical-stage biopharmaceutical company acquiring and developing novel therapeutics at the leading edge of cancer research. for more information about leap therapeutics, visit http://www.leaptx.com or our public filings with the sec that are available via edgar at http://www.sec.gov or via http://www.investors.leaptx.com.